LASA vs LINCOLN: Stock Comparison
LINCOLN PHARMA is the larger company by market capitalisation. LINCOLN PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LASA leads 0; LINCOLN leads 9 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LASA | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LASA | LINCOLN |
|---|---|---|
| Live Price | ₹6.52 | ₹510.85 |
| Day Change | -2.54% | -0.72% |
| Volume | 46,913 | 61,149 |
| 52-Week High | ₹12.48 | ₹770 |
| 52-Week Low | ₹5.67 | ₹440 |
| Distance from 52W High | -47.76% | -33.66% |
Valuation
| Metric | LASA | LINCOLN |
|---|---|---|
| Market Cap | ₹27 Cr | ₹1,023 Cr |
| P/E Ratio | — | 10.61x |
| P/B Ratio | — | 1.35x |
| EPS | ₹-0.71 | ₹18.09 |
| Book Value | ₹9.9 | ₹378.25 |
| Dividend Yield | 0% | 0.35% |
Growth
| Metric | LASA | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 11.4% |
| EPS Growth (TTM YoY) | 0% | 0.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | LASA | LINCOLN |
|---|---|---|
| ROE | -68.7% | 11.6% |
| ROCE | -57.92% | 10.97% |
| Net Margin | -135.6% | 13.1% |
| Operating Margin | -136.12% | 17.38% |
| Debt to Equity | 0.2x | 0.01x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | LASA | LINCOLN |
|---|---|---|
| Promoter Holding | 53.65% | 49.78% |
| FII Holding | 0% | 4.6%▼ 0.59 pp |
| DII Holding | 0% | 0.27%▼ 0.82 pp |
| Public Holding | 46.35% | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LASA and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.